RU97112857A - NEW IMMUNOTHERAPEUTIC ARILAMIDES - Google Patents
NEW IMMUNOTHERAPEUTIC ARILAMIDESInfo
- Publication number
- RU97112857A RU97112857A RU97112857/04A RU97112857A RU97112857A RU 97112857 A RU97112857 A RU 97112857A RU 97112857/04 A RU97112857/04 A RU 97112857/04A RU 97112857 A RU97112857 A RU 97112857A RU 97112857 A RU97112857 A RU 97112857A
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- substituted
- alkyl containing
- compound
- phenyl
- Prior art date
Links
- 230000001024 immunotherapeutic Effects 0.000 title 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 12
- -1 carbethoxy, carbomethoxy, carbopropoxy, acetyl Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
Claims (11)
где Аr обозначает (i) линейный, разветвленный или циклический, не замещенный алкил, содержащий от 1 до 12 атомов углерода, (ii) линейный разветвленный или циклический, замещенный алкил, содержащий от 1 до 12 атомов углерода; iii) фенил; iv) фенил, замещенный одним или несколькими заместителями, каждый из которых, независимо, выбран из группы, состоящей из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенной амино группы, алкила, содержащего от 1 до 10 атомов углерода, алкокси, содержащего от 1 до 10 атомов углерода, или галогена; v) гетероцикл; или vi) гетероцикл, замещенный одним или несколькими заместителями, каждый из которых, независимо, выбран из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, алкила, содержащего от 1 до 10 атомов углерода, алкокси, содержащего от 1 до 10 атомов углерода, или галогена;
R обозначает -Н, алкил, содержащий от 1 до 10 атомов углерода, -СН2ОН, -СН2СН2ОН или-CH2COZ, где Z обозначает алкокси, содержащий от 1 до 10 атомов углерода, бензилокси или NHR1, где R1 обозначает Н или алкил, содержащий от 1 до 10 атомов углерода; и Y обозначает i) фенил или гетероциклическое кольцо,
незамещенное или замещенное одним или несколькими заместителями, каждый из которых, независимо, выбран из группы, состоящей из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, алкила, содержащего от 1 до 10 атомов углерода, алкокси, содержащего от 1 до 10 атомов углерода, или галогена; или ii) нафтил.1. The compound having the formula
where Ar is (i) linear, branched or cyclic, unsubstituted alkyl containing from 1 to 12 carbon atoms, (ii) linear, branched or cyclic, substituted alkyl containing from 1 to 12 carbon atoms; iii) phenyl; iv) phenyl substituted with one or more substituents, each independently selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino groups, alkyl containing from 1 to 10 carbon atoms, alkoxy containing from 1 to 10 carbon atoms, or halogen; v) heterocycle; or vi) a heterocycle substituted with one or more substituents, each independently selected from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl containing from 1 to 10 carbon atoms, alkoxy containing from 1 to 10 carbon atoms, or halogen;
R is —H, alkyl containing from 1 to 10 carbon atoms, —CH 2 OH, —CH 2 CH 2 OH or —CH 2 COZ, where Z is alkoxy containing from 1 to 10 carbon atoms, benzyloxy or NHR 1 , where R 1 denotes H or alkyl containing from 1 to 10 carbon atoms; and Y is i) a phenyl or heterocyclic ring,
unsubstituted or substituted by one or more substituents, each of which is independently selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl containing from 1 to 10 carbon atoms, alkoxy containing from 1 to 10 carbon atoms, or halogen; or ii) naphthyl.
где Аr обозначает (i) линейный, разветвленный или циклический, не замещенный алкил, содержащий от 1 до 12 атомов углерода, (ii) линейный разветвленный или циклический, замещенный алкил, содержащий от 1 до 12 атомов углерода; iii) фенил; iv) фенил, замещенный одним или несколькими заместителями, каждый из которых, независимо, выбран из группы, состоящей из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, замещенной амино группы, алкила, содержащего от 1 до 10 атомов углерода, алкокси, содержащего от 1 до 10 атомов углерода, или галогена; v) гетероцикл; или vi) гетероцикл, замещенный одним или несколькими заместителями, каждый из которых, независимо, выбран из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, алкила, содержащего от 1 до 10 атомов углерода, алкокси, содержащего от 1 до 10 атомов углерода, или галогена;
R обозначает -Н, алкил, содержащий от 1 до 10 атомов углерода, -СН2ОН, -СН2СН2ОН или -CH2COZ, где Z обозначает алкокси, содержащий от 1 до 10 атомов углерода, бензилокси или NHR1, где R1 обозначает Н или алкил, содержащий от 1 до 10 атомов углерода; и Y обозначает i) фенил или гетероциклическое кольцо,
незамещенное или замещенное одним или несколькими заместителями, каждый из которых, независимо, выбран из группы, состоящей из группы, состоящей из нитро, циано, трифторметила, карбэтокси, карбометокси, карбопропокси, ацетила, карбамоила, ацетокси, карбокси, гидрокси, амино, алкила, содержащего от 1 до 10 атомов углерода, алкокси, содержащего от 1 до 10 атомов углерода, или галогена; или ii) нафтил.7. A method of reducing the level of TNFα in mammals, which includes the introduction of an effective amount of a compound of the formula
where Ar is (i) linear, branched or cyclic, unsubstituted alkyl containing from 1 to 12 carbon atoms, (ii) linear, branched or cyclic, substituted alkyl containing from 1 to 12 carbon atoms; iii) phenyl; iv) phenyl substituted with one or more substituents, each independently selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino groups, alkyl containing from 1 to 10 carbon atoms, alkoxy containing from 1 to 10 carbon atoms, or halogen; v) heterocycle; or vi) a heterocycle substituted with one or more substituents, each independently selected from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl containing from 1 to 10 carbon atoms, alkoxy containing from 1 to 10 carbon atoms, or halogen;
R is —H, alkyl containing from 1 to 10 carbon atoms, —CH 2 OH, —CH 2 CH 2 OH or —CH 2 COZ, where Z is alkoxy containing from 1 to 10 carbon atoms, benzyloxy or NHR 1 , where R 1 denotes H or alkyl containing from 1 to 10 carbon atoms; and Y is i) a phenyl or heterocyclic ring,
unsubstituted or substituted by one or more substituents, each independently selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl, containing from 1 to 10 carbon atoms, alkoxy containing from 1 to 10 carbon atoms, or halogen; or ii) naphthyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/366,618 US5801195A (en) | 1994-12-30 | 1994-12-30 | Immunotherapeutic aryl amides |
US08/366,618 | 1994-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97112857A true RU97112857A (en) | 1999-06-27 |
RU2162839C2 RU2162839C2 (en) | 2001-02-10 |
Family
ID=23443777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97112857/04A RU2162839C2 (en) | 1994-12-30 | 1995-11-20 | Arylamides, pharmaceutical composition and method of inhibition of tnf2-activated retrovirus replication |
Country Status (19)
Country | Link |
---|---|
US (4) | US5801195A (en) |
EP (1) | EP0800505B1 (en) |
JP (2) | JP4052665B2 (en) |
KR (1) | KR100374088B1 (en) |
AT (1) | ATE206107T1 (en) |
AU (1) | AU717100B2 (en) |
CA (1) | CA2208746C (en) |
CZ (1) | CZ203797A3 (en) |
DE (1) | DE69522961T2 (en) |
DK (1) | DK0800505T3 (en) |
ES (1) | ES2165927T3 (en) |
FI (1) | FI972710A (en) |
HU (1) | HUT77125A (en) |
NZ (4) | NZ536861A (en) |
PL (1) | PL182057B1 (en) |
PT (1) | PT800505E (en) |
RU (1) | RU2162839C2 (en) |
SK (1) | SK86797A3 (en) |
WO (1) | WO1996020915A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
DK0918746T3 (en) * | 1996-08-12 | 2003-08-04 | Celgene Corp | Immunotherapeutic agents and their use in reducing cytokine levels |
US5932618A (en) * | 1996-11-04 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Anti-viral agents and methods relating to the use thereof |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
GB0202776D0 (en) * | 2002-02-06 | 2002-03-27 | Axis Shield Asa | Assay |
US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2003086373A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
MXPA04009997A (en) * | 2002-04-12 | 2004-12-13 | Celgene Corp | Modulation of stem and progenitor cell differentiation, assays, and uses thereof. |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
JP2005530780A (en) | 2002-05-17 | 2005-10-13 | セルジーン・コーポレーション | Methods and compositions using selective cytokine inhibitors for the treatment and management of cancer and other diseases |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
BR0315316A (en) * | 2002-10-15 | 2005-08-16 | Celgene Corp | Methods of treating, preventing or controlling a myelodysplastic syndrome, and reducing or preventing an adverse effect associated with the administration of a second active ingredient to a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, unit dosage form, and kit |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
AU2003226361B2 (en) * | 2002-11-06 | 2009-01-22 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
EP1567154A4 (en) | 2002-11-06 | 2006-05-31 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
MXPA05005161A (en) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Methods of usig and compositions comprising (-)-3- (3, 4- dimethoxy -phenyl)-3 -(1-oxo-1, 3-dihydro- isoindol- 2-yl)- propionamide. |
AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
WO2005041684A2 (en) | 2003-08-06 | 2005-05-12 | Senomyx Inc. | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
JP2007511618A (en) | 2003-11-19 | 2007-05-10 | シグナル ファーマシューティカルズ,エルエルシー | Indazole compounds and methods of use as protein kinase inhibitors |
BRPI0418743A (en) * | 2004-04-14 | 2007-09-18 | Celgene Corp | methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit |
CN1972684A (en) * | 2004-04-23 | 2007-05-30 | 细胞基因公司 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
KR20070085454A (en) * | 2004-10-28 | 2007-08-27 | 셀진 코포레이션 | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
RU2449999C2 (en) * | 2006-01-18 | 2012-05-10 | Эвольва Са | Ppar modulators |
ES2640453T3 (en) | 2006-04-21 | 2017-11-03 | Senomyx, Inc. | Processes for preparing solid flavoring compositions |
WO2008089461A1 (en) | 2007-01-18 | 2008-07-24 | Evolva Sa | Substituted 1,3-dioxanes useful as ppar modulators |
ES2609825T3 (en) * | 2007-01-18 | 2017-04-24 | Evolva Sa | 1,3-substituted dioxanes useful as PPAR modulators |
CA2718412A1 (en) * | 2008-03-24 | 2009-10-01 | Celgene Corporation | Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
EA201171035A1 (en) | 2009-02-10 | 2012-02-28 | Селджин Корпорейшн | COMPOSITIONS, INCLUDING MODULATORS PDE4, AND METHOD OF THEIR APPLICATION FOR THE TREATMENT, PREVENTION AND SUPPORT OF TUBERCULOSIS |
US9408831B2 (en) | 2010-04-07 | 2016-08-09 | Celgene Corporation | Methods for treating respiratory viral infection |
EP2583098B1 (en) | 2010-06-15 | 2018-08-08 | Celgene Corporation | Biomarkers for the treatment of psoriasis |
AR085013A1 (en) | 2011-01-26 | 2013-08-07 | Sanofi Aventis | SUBSTITUTED 3-HETEROAROILAMINE-PROPIONIC ACID DERIVATIVES AND ITS USE AS PHARMACEUTICAL SUBSTANCES |
KR20140063808A (en) * | 2011-09-14 | 2014-05-27 | 셀진 코포레이션 | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
WO2015175956A1 (en) | 2014-05-16 | 2015-11-19 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
MX2016014384A (en) | 2014-06-23 | 2017-01-20 | Celgene Corp | Apremilast for the treatment of a liver disease or a liver function abnormality. |
KR101749229B1 (en) | 2014-12-22 | 2017-06-20 | 엘지디스플레이 주식회사 | Image Display Method And Image Display Device |
WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB919073A (en) * | 1960-09-15 | 1963-02-20 | Farmaceutici Italia | Benzylamine derivatives |
NL300271A (en) * | 1962-11-09 | |||
US4173652A (en) * | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
DK159079A (en) * | 1978-05-18 | 1979-11-19 | Pfizer | PROCEDURE FOR THE PREPARATION OF 4-AMINO-2-PIPERIDINOQUINAZOLINE DERIVATIVES OR ACID ADDITIONAL SALTS THEREOF |
SE434638B (en) * | 1980-06-06 | 1984-08-06 | Lekemedelsfabriken Medica Ab | NEW THERAPEUTIC WORLDFUL TAURIN DERIVATIVES AND THEIR PREPARATION |
DE3022002A1 (en) * | 1980-06-12 | 1981-12-17 | Bayer Ag, 5090 Leverkusen | 1,4-DIHYDROPYRIDIN-4-CARBONIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF AND THE MEDICINAL PRODUCTS CONTAINING THEM |
DE3041812A1 (en) | 1980-11-06 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | BASICLY SUBSTITUTED 5-PHENYL TETRAZOLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINE |
CA1206964A (en) * | 1980-11-12 | 1986-07-02 | Nobuo Shinma | Tetra-substituted benzene derivatives |
ZA817662B (en) * | 1980-11-12 | 1982-10-27 | Hoffmann La Roche | Tetra-substituted benzene derivatives |
US4440941A (en) * | 1980-12-22 | 1984-04-03 | Usv Pharmaceutical Corporation | Aroyl-aminoacids, amides and esters thereof |
CH656382A5 (en) * | 1983-10-24 | 1986-06-30 | Sandoz Ag | SULFOXIDES, METHOD FOR THEIR PRODUCTION AND THEIR USE. |
JPH0714949B2 (en) * | 1986-09-22 | 1995-02-22 | 恭光 田村 | Method for producing optically active hexanoic acid derivative |
IL84944A (en) * | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
US4820828A (en) * | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
GB2202468A (en) | 1987-03-25 | 1988-09-28 | Smidth & Co As F L | Cyclone |
JPH01203351A (en) * | 1988-02-05 | 1989-08-16 | Mitsui Petrochem Ind Ltd | 1,4-dihydroxynaphthalene derivative and medicine |
US5298502A (en) * | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
JP2897307B2 (en) * | 1990-01-09 | 1999-05-31 | 三菱化学株式会社 | Agricultural and horticultural fungicides containing pyrazole amides as active ingredients |
DK220890D0 (en) * | 1990-09-14 | 1990-09-14 | Ole Buchardt | PROCEDURE FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES |
DE4201047A1 (en) * | 1992-01-17 | 1993-07-22 | Bayer Ag | SUBSTITUTED ISOXAZOLE CARBONIC ACID AMIDES |
AU3441193A (en) * | 1992-04-14 | 1993-11-18 | Sphinx Pharmaceuticals Corporation | Polyhydroxylated dibenz (C,E) azepines as protein kinase C inhibitors |
US5298652A (en) * | 1992-12-08 | 1994-03-29 | Hoffmann-La Roche Inc. | N-substituted glycines, inhibitors of phospholipase A2 |
WO1994014783A1 (en) * | 1992-12-25 | 1994-07-07 | Nippon Soda Co., Ltd. | Heterocyclic derivative and pest control agent |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
JPH07233148A (en) * | 1993-12-27 | 1995-09-05 | Terumo Corp | Piperidine derivative and medicinal preparation containing the same |
IT1271026B (en) * | 1994-10-21 | 1997-05-26 | Isagro Ricerca Srl | DERIVATIVES OF B-AMINOPROPIONIC ACID WITH FUNGICIDE ACTIVITY |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
KR100332273B1 (en) * | 1995-07-26 | 2002-06-20 | 디. 제이. 우드, 스피겔 알렌 제이 | N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
PT871439E (en) * | 1996-01-02 | 2004-08-31 | Aventis Pharma Inc | SUBSTITUTED HYDROXYLIC ACID COMPOUNDS (ARYLETHYLETHYLRENE ARYLMETHYL OR HETEROYARMETHYL) |
-
1994
- 1994-12-30 US US08/366,618 patent/US5801195A/en not_active Expired - Fee Related
-
1995
- 1995-11-20 PL PL95321072A patent/PL182057B1/en not_active IP Right Cessation
- 1995-11-20 SK SK867-97A patent/SK86797A3/en unknown
- 1995-11-20 NZ NZ536861A patent/NZ536861A/en unknown
- 1995-11-20 NZ NZ501632A patent/NZ501632A/en unknown
- 1995-11-20 AT AT95941438T patent/ATE206107T1/en not_active IP Right Cessation
- 1995-11-20 AU AU42859/96A patent/AU717100B2/en not_active Ceased
- 1995-11-20 WO PCT/US1995/015126 patent/WO1996020915A1/en not_active Application Discontinuation
- 1995-11-20 HU HU9701847A patent/HUT77125A/en unknown
- 1995-11-20 EP EP95941438A patent/EP0800505B1/en not_active Expired - Lifetime
- 1995-11-20 JP JP52097996A patent/JP4052665B2/en not_active Expired - Fee Related
- 1995-11-20 NZ NZ297649A patent/NZ297649A/en unknown
- 1995-11-20 DE DE69522961T patent/DE69522961T2/en not_active Expired - Fee Related
- 1995-11-20 CA CA002208746A patent/CA2208746C/en not_active Expired - Fee Related
- 1995-11-20 PT PT95941438T patent/PT800505E/en unknown
- 1995-11-20 KR KR1019970704511A patent/KR100374088B1/en not_active IP Right Cessation
- 1995-11-20 ES ES95941438T patent/ES2165927T3/en not_active Expired - Lifetime
- 1995-11-20 DK DK95941438T patent/DK0800505T3/en active
- 1995-11-20 RU RU97112857/04A patent/RU2162839C2/en not_active IP Right Cessation
- 1995-11-20 NZ NZ501631A patent/NZ501631A/en unknown
- 1995-11-20 CZ CZ972037A patent/CZ203797A3/en unknown
-
1996
- 1996-10-15 US US08/729,847 patent/US5736570A/en not_active Expired - Fee Related
-
1997
- 1997-06-23 FI FI972710A patent/FI972710A/en not_active IP Right Cessation
-
1998
- 1998-08-25 US US09/139,614 patent/US6046221A/en not_active Expired - Fee Related
-
2000
- 2000-02-09 US US09/500,899 patent/US6284780B1/en not_active Expired - Fee Related
-
2007
- 2007-09-10 JP JP2007234561A patent/JP2008019269A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU97112857A (en) | NEW IMMUNOTHERAPEUTIC ARILAMIDES | |
RU99113849A (en) | IMMUNOTHERAPEUTIC IMIDES / AMIDES AS A PDE IV INHIBITOR AND TNF | |
RU98105689A (en) | ALPHA TUMOR NECROSIS FACTOR INHIBITORS | |
RU97112858A (en) | SUBSTITUTED IMIDES AS INHIBITORS | |
RU98108602A (en) | Succinimide and maleimide cytokine inhibitors | |
EP1004572A3 (en) | Amines as inhibitors of TNF alpha | |
CA2208746A1 (en) | Novel immunotherapeutic aryl amides | |
AU3607895A (en) | 1-acyl-4-aliphatylaminopiperidine compounds | |
EA199801047A1 (en) | Mixed causal inlazole and their use as inhibitors of phosphodiesterrase (PDE) TYPE IV and the tumor necrosis factor (TNF) | |
EA199800882A1 (en) | Derivatives of Mixed Indazols, Their Use as Photophodiesterrase Inhibitors (PDE) IV and Obtaining Tumor Necrosis Factor (TNF) | |
FR2639349B1 (en) | NOVEL CHROMANE DERIVATIVES ACTIVE IN THE CENTRAL NERVOUS SYSTEM, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
KR920021547A (en) | Azole derivatives | |
RU97112903A (en) | IMID / AMIDE ETHERS, PHARMACEUTICAL COMPOSITION ON THE BASIS AND METHOD FOR REDUCING THE MONOGRAPHY LEVEL (TNFA) IN MAMMALS | |
ATE41772T1 (en) | POLYMETHOXYBENZYL PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES. | |
FR2707089B1 (en) | New phosphonic acid derivatives, process for their preparation and pharmaceutical compositions containing them. | |
IE832680L (en) | Nitrosourea derivatives. | |
EP0051190A3 (en) | N-(amino(or hydroxy) phenethyl)-1,2,3,4-tetrahydroisoquinolines, precursors thereof, and methods of preparation | |
ES8500939A1 (en) | 5-Amino-1,2-dithiol-3-one derivatives, their preparation and medicinal compositions containing them. | |
ATE25968T1 (en) | 1,1-DIPHENYLPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
SE8000138L (en) | NEW 3-CYCLOPENTANE-1,2 '(1'H) -NOTAL DERIVATIVES, PREPARATION OF THEM AND MEDICINAL CONTAINING THEM | |
RU99100316A (en) | NEW AMINO ACID DERIVATIVES AND THEIR APPLICATION AS THROMBIN INHIBITORS | |
RU98107030A (en) | ALPHA-ISONITROSOACETETO ACETIC ACID DERIVATIVES AND FUNGICIDAL COMPOSITION |